V. Ahooja

Pharmacological Prevention of Thromboembolism in Patients with Left Ventricular Dysfunction

D. Thatai, P. Pullicino, V. Ahooja, 2006, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes

S. Verma, A. Yan, S. Goodman, 2021, Cardiovascular Diabetology.

Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.

S. Verma, R. Goldenberg, J. Gilbert, 2020, Canadian journal of diabetes.

Hypertension in Racial and Ethnic Minorities

J. Flack, Samar A. Nasser, S. O’Connor, 2007 .

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

S. Verma, C. Lam, V. Ahooja, 2019, Journal of the American Heart Association.

Treatment Inertia in Patients With Familial Hypercholesterolemia

Lawrence A Leiter, M. Tan, A. Langer, 2021, Journal of the American Heart Association.

Canadian Cardiovascular Society - Canadian Heart Failure Society Focused Clinical Practice Update of Patients with Differing Heart Failure Phenotypes.

A. Ducharme, J. Andrade, J. Ezekowitz, 2023, The Canadian journal of cardiology.

Antithrombotic Therapies in Canadian Atrial Fibrillation Patients with Concomitant Coronary Artery Disease: Insights from the CONNECT AF+PCI-II Program.

A. Bagai, W. Cantor, A. Yan, 2023, Journal of cardiology.

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

G. Mancini, J. Bergeron, M. Gupta, 2022, CJC open.